TNKS2

Poly [ADP-ribose] polymerase tankyrase-2

78,842 patent compounds predicted against TNKS2, 46,383 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL167751	1.00	19/20
Tricyclazole (SCHEMBL23082)	0.66	17/20
SCHEMBL120735	0.54	17/20
SCHEMBL165829	1.00	16/20
SCHEMBL120737	0.61	14/20
SCHEMBL215530	0.64	13/20
SCHEMBL169194	0.64	13/20
SCHEMBL179040	0.71	12/20
SCHEMBL162259	0.53	12/20
SCHEMBL164147	0.54	10/20
SCHEMBL146025	0.61	9/20
SCHEMBL147895	0.50	9/20
SCHEMBL141348	0.66	8/20
SCHEMBL74712	0.55	8/20
SCHEMBL148227	0.50	8/20
SCHEMBL146851	0.49	8/20
SCHEMBL56854	0.54	7/20
SCHEMBL129916	0.52	7/20
SCHEMBL147097	0.51	7/20
SCHEMBL168935	0.44	6/20

Germline variants in TNKS2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TNKS2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TNKS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations	PHASE1/PHASE2	COMPLETED
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Telaglenastat + Talazoparib In Prostate Cancer	PHASE2	UNKNOWN
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a TNKS2 binder may also engage these)

Protein	Name	Similarity
Q3UES3	—	1.000	Q3UES3 →
TNKS	Poly [ADP-ribose] polymerase tankyrase-1	1.000	landscape →
Q6PFX9	—	1.000	Q6PFX9 →
Q9VBP3	—	0.995	Q9VBP3 →
G5E8K5	—	0.994	G5E8K5 →
Q01484	—	0.992	Q01484 →
Q8C8R3	—	0.992	Q8C8R3 →
O70511	—	0.991	O70511 →
Q02357	—	0.990	Q02357 →
Q12955	—	0.989	Q12955 →
P16157	—	0.989	P16157 →
Q5TYM7	—	0.989	Q5TYM7 →
Q60772	—	0.988	Q60772 →
Q08E43	—	0.986	Q08E43 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.984	landscape →
P42773	—	0.984	P42773 →
Q4R544	—	0.984	Q4R544 →
A7E2S9	—	0.984	A7E2S9 →
Q7T163	—	0.983	Q7T163 →
P25799	—	0.983	P25799 →
Q4R3S3	—	0.983	Q4R3S3 →
DAPK1	Death-associated protein kinase 1	0.983	landscape →
Q99NH0	—	0.983	Q99NH0 →
P51480	—	0.982	P51480 →
O75179	—	0.982	O75179 →
Q65XV2	—	0.982	Q65XV2 →
Q9EQG6	—	0.982	Q9EQG6 →
Q80YE7	—	0.982	Q80YE7 →
D3J162	—	0.982	D3J162 →
A0PJZ0	—	0.982	A0PJZ0 →